missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Palivizumab Humanized Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Marke: Invitrogen™ MA560177
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.
Spezifikation
| Palivizumab Humanized | |
| Recombinant Monoclonal | |
| Unconjugated | |
| MEDI-493; Synagis | |
| Protein A | |
| RUO | |
| Virus | |
| Antibody | |
| IgG1 |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 7.53 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur